Consensus Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Real-time Estimate Cboe BZX Other stock markets 03:10:35 2024-04-25 pm EDT			5-day change	1st Jan Change
1.08 ^USD	-0.92%		-16.02%	+24.28%

Apr. 24	Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Evolution of the average Target Price on Karyopharm Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

cba842f6e0c.6irDSasG61PhkhI85E-xFWdpaL6ZpLTWn5ui_VuYvT4.uWf2L91Av2Wr-0pmli72eypaKfj_yN2Hru6Tiiqr7Uq4Ra4BzzCRBrT4ZQ~4d37c26d4b5b968a64682a28e0a84fad

Analyst Recommendations on Karyopharm Therapeutics Inc.

RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating	Nov. 03	MT
Wedbush Trims Karyopharm Therapeutics' PT to $3 From $4, Sees Limited Upside Near Term; Maintains Neutral Rating	Nov. 03	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Equal-Weight Rating	23-08-07	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Outperform Rating	23-08-03	MT
Wedbush Cuts Karyopharm Therapeutics' PT to $4 From $7, Lowers Peak Sales Estimate for Selinexor; Keeps Neutral Rating	23-07-26	MT
Baird Adjusts Karyopharm Therapeutics' Price Target to $10 From $14, Keeps Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Karyopharm Therapeutics Price Target to $10 From $16, Maintains Buy Rating	23-05-05	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Outperform Rating	23-05-05	MT
Wedbush Lifts Karyopharm Therapeutics' Price Target to $7 From $6 After Adding in Valuation for Selinexor in 1L Myelofibrosis, Keeps Neutral Rating	23-04-19	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $6 From $7, Maintains Outperform Rating	23-02-16	MT
Piper Sandler Starts Karyopharm Therapeutics at Overweight With $8 Price Target	23-01-19	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Outperform Rating	23-01-13	MT
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $16 From $18, Maintains Buy Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Market Perform Rating	23-01-10	MT
Wedbush Trims Karyopharm Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $6 From $5, Maintains Market Perform Rating	22-11-04	MT
RBC Upgrades Karyopharm Therapeutics to Outperform From Sector Perform, Boosts Price Target to $10 From $7, Cites 'Improving Uptake' for Xpovio, 'Promising' Mylofibrosis Data	22-11-04	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	22-09-09	MT
Morgan Stanley Cuts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	22-09-09	MT
Baird Lowers Karyopharm Therapeutics Price Target to $14 From $17, Maintains Outperform Rating	22-08-05	MT
Barclays Adjusts Price Target on Karyopharm Therapeutics to $8 From $14, Reiterates Overweight Rating	22-08-05	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Sector Perform Rating	22-08-05	MT
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $18 From $21, Reiterates Buy Rating	22-08-05	MT
Wedbush Adjusts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Neutral Rating	22-08-05	MT
RBC Raises Price Target on Karyopharm Therapeutics to $9 From $8, Maintains Sector Perform Rating	22-07-07	MT